血栓弹力图在老年急性冠脉综合征患者抗血小板药物治疗中的应用

孙阿林; 庞军涛; 张振; 高安路; 李晓东; 王健

doi:10.13201/j.issn.1001-1439.2017.05.009

血栓弹力图在老年急性冠脉综合征患者抗血小板药物治疗中的应用

- 1. 潍坊市人民医院重症医学科(山东潍坊, 261041);
- 2. 潍坊市人民医院心内科

详细信息

通讯作者: 王健,E-mail:13953670058@163.com

中图分类号: R541.4

收稿日期: 2016-08-19

修回日期: 2016-12-17

Applications of thrombelastogram in antiplatelet therapy in elderly patients with acute coronary syndrome

- 1. Intensive Care Unit;
- 2. Department of Cardiology, Weifang People's Hospital, Weifang, Shandong, 261041, China

More Information

Corresponding author: WANG Jian, E-mail: 13953670058@163.com

Received Date: 19 August 2016

Revised Date: 17 December 2016

摘要

摘要: 目的：应用血栓弹力图测定老年急性冠脉综合征（ACS）患者应用不同抗血小板药物后的血小板抑制率，评估药物疗效并寻找改善抗血小板药物抵抗的对策。方法：选取60周岁以上老年ACS患者280例，在常规药物治疗基础中给予抗血小板药物治疗，随机分为单抗组（A组）和双抗组（B组），A组随机分为阿司匹林组（A1）40例、氯吡格雷组（A2）40例、替格瑞洛组（A3）40例，B组随机分为阿司匹林+氯吡格雷组（B1）80例、阿司匹林+替格瑞洛组（B2）80例，共5组。各组患者服用药物1个月后，应用血栓弹力图测定血小板经AA途径诱导的抑制率及经ADP途径诱导的抑制率，对各组患者不同药物的血小板抑制率及抗血小板有效率进行比较，并统计患者6个月内的出血或心血管缺血等不良事件发生情况；对存在抗血小板抵抗的患者，采取加大药物剂量或更换抗血小板药物的方式以改善血小板抵抗。结果：B组抗血小板有效率明显优于A组（P<0.05），B2组经ADP途径诱导的抑制率及有效率明显优于B1组（P<0.05）；A1组抗血小板无效的患者更换药物为替格瑞洛，以及B2组抗血小板无效的患者替格瑞洛加量均获得了良好的效果（P<0.05），且未增加任何出血风险（P>0.05），并可降低心血管不良事件的发生率（P<0.05）。结论：阿司匹林联合替格瑞洛双联抗血小板疗法疗效确切，并可降低心血管事件的发生率；对存在血小板抵抗患者更换或加量抗血小板药物是改善抗血小板药物抵抗，取得临床疗效的好对策，且并不增加出血风险。
- 血栓弹力图 /
- 血小板抑制率 /
- 冠心病 /
- 血小板抵抗
Abstract: Objective: To observe the curative effect of different antiplatelet drugs in elderly patients with acute coronary syndromes (ACS) and look for strategies to ameliorate the antiplatelet drug resistance through monitoring platelet inhibition rate by using thrombelastogram (TEG).Method: The elderly patient with ACS(n=280)with oral antiplatelet drugs on the basis of the routine drugs were randomly divided into single resistance group (A group) and double resistance group (B group), the patients in group A were randomly divided into aspirin group (A1 group, n=40 cases), clopidogrel group (A2 group, n=40) and ticagrelor group(A3 group, n=40), while the patients in group B were randomly divided into aspirin + clopidogrel group (B1 group, n=80) and aspirin + ticagrelor group (B2 group, n=80). The AA induced platelet inhibition rate and the ADP induced inhibition rate were measured by using TEG after one month of taking drugs.The platelet inhibition rates and antiplatelet effective rates of different drugs were compared, and the bleeding or adverse events such as cardiovascular ischemia in 6 months were collected. Increasing dosage or substituting drugs were taken to improve platelet resistance.Result: The antiplatelet efficient rate in B group was obviously higher than that in group A (P<0.05). The ADP induced inhibition rate and the effective rate in B2 group were obviously higher than those in B1 group (P<0.05). The anti-platelet drugs failed to work in patients of A1 group were replaced with ticagrelor, while those in B2 group increased the dosage of ticagrelor. All of the above patient had good antiplatelet efficacy without an increase of bleeding risk and with an decrease of adverse cardiovascular events(P<0.05).Conclusion: Aspirin combination with ticagrelor dual antiplatelet therapy has obvious curative effect, can reduce the incidence of adverse events. Replace or add antiplatelet drugs are good strategies to improve the antiplatelet drug resistance, and does not increase the risk of bleeding.
- thromboelastogram /
- platelet inhibition rate /
- coronary heart disease /
- antiplatelet drug resistance

HTML全文

参考文献(16)

[1]	PAN Y, WANG A, LIU G, et al. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke[J]. J Am Heart Assoc, 2014, 17:e000912-e000912.
[2]	GARG P K, SINGH J, SINGH T P, et al. Evaluation of the Relative Efficacy and Safety of Prasugrel and Clopidogrel in Medically Managed High Risk UA/NSTEMI ACS Population[J]. 2015, 4:809-817.
[3]	GASPARYAN A Y, WATSON T, LIP G Y. The role of aspirin in cardiovascular prevention:implications of aspirin resistance[J]. Am Coll Cardiol, 2008,51:1829-1843.
[4]	XU Z, LI Y, YANG X, et al. Early detection of coagulation abnormalities in patients at nutritional risk:the novel role of thromboelastography[J]. Am Surg, 2014,80:81-86.
[5]	邱林,龚艳君. 血栓弹力图在经皮冠状动脉介入治疗中的应用[J]. 中国介入心脏病学杂志,2014,22(9):582-585.
[6]	王璐璐, 王雁. 阿司匹林抵抗与其分子生物学机制[J]. 中华老年心脑血管病杂志, 2016, 18(4):431-433.
[7]	顾永丽, 孙增先. 阿司匹林抵抗与氯吡格雷抵抗的研究进展[J]. 中国医院药学杂志, 2016, 36(10):866-869.
[8]	SAMBU N, RADHAKRISHMAN A, DENT H, et al. Personalised antiplatelet in stent thrombosis:observations from the Clopidogrel Resistance in Stent Thrombosis (crest) registry[J]. Heart,2012,98:706-711.
[9]	NEUBAUER H, KAISER A F, ENDRES H G, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy[J]. BMC Med,2011,9:3.
[10]	阮爱兵. 氯吡格雷抵抗机制的研究进展[J]. 河北联合大学学报(医学版), 2015, 34(4):79-82.
[11]	LAU W C, GURBEL P A, WATKINS P B, et al. Contribution of hepatic cytochrome P4503A4 metabolic activity to the phenomenon of clopidogrel resistance[J]. Circulation,2004,109:166-171.
[12]	FEHER G, FEHER A, PUSCH G, et al. Clinical importance of aspirin and clopidogrel resistance[J]. World J Cardiol, 2010,2:171-186.
[13]	王婧, 袁晋青. 血小板功能检测指导下个体化抗血小板治疗的研究进展[J]. 中华临床医师杂志:电子版, 2013(12):5507-5509.
[14]	DAVIS E M, KNEZEVICH J T, TEPLY R M. Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality:a review of ticagrelor[J]. Clin Pharmacol,2013,19:67-83.
[15]	王热华,林锋,陈诗,等. 血栓弹力图评估阿司匹林和氯吡格雷血小板抑制率的临床应用[J].中国老年学杂志,2013,33(17):4111-4112.
[16]	张兵兵,唐海沁,张勇,等.血栓弹力图评价冠心病患者抗血小板药物治疗的临床疗效[J].中国临床保健杂志,2015,18(4):370-372.